Pearls from 2/2/21 Medicine LEADS

Thursday, February 4, 2021

The Feb. 2, 2021 session of Duke Medicine LEADS featured E. Magnus Ohman, MD, FACC, presenting "New Medications and New Uses: Advanced Cardiovascular Prevention Strategies."

Here are pearls and takeaways from the session:

  1. SGLT2 inhibitors are indicated for Type 2 diabetics for high risk primary prevention or secondary prevention of CVD.

  2. SGLT2 inhibitors are indicated for patient with HFrEF with or without diabetes.

  3. Use your clinical judgment before using SGLT2 inhibitors in patients with severe PAD open wounds, DKA, or an eGFR <45.

  4. If patients have symptoms suspicious for CAD and do not require emergent invasive testing, consider getting a CTA to evaluate their coronary vasculature. Coronary CTA provide similar diagnostic yield to an invasive strategy and allows an easy way to exclude CAD. In addition, patients who have Coronary CTA receive better preventative care after their diagnosis compared with those that have only stress testing to detect CAD.

  5. In patients with CVD and PVD, the Compass Trial demonstrated that Rivaroxaban at 2.5 mg po BID plus ASA 81 mg daily reduced the risk of cardiovascular events. 

Watch the recorded session

Duke Medicine Learning, Education, and Discussion Series (LEADS) takes place each Tuesday at 12 p.m. Learn more and see schedule of upcoming sessions.